PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
VIR vs. VERU
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between VIR and VERU is 0.22, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.0
Correlation: 0.2

Performance

VIR vs. VERU - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Vir Biotechnology, Inc. (VIR) and Veru Inc. (VERU). The values are adjusted to include any dividend payments, if applicable.

-80.00%-70.00%-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%NovemberDecember2025FebruaryMarchApril
-60.20%
-72.47%
VIR
VERU

Key characteristics

Sharpe Ratio

VIR:

-0.48

VERU:

-0.27

Sortino Ratio

VIR:

-0.48

VERU:

0.42

Omega Ratio

VIR:

0.95

VERU:

1.06

Calmar Ratio

VIR:

-0.45

VERU:

-0.32

Martin Ratio

VIR:

-1.36

VERU:

-0.57

Ulcer Index

VIR:

31.21%

VERU:

54.52%

Daily Std Dev

VIR:

88.17%

VERU:

115.86%

Max Drawdown

VIR:

-93.28%

VERU:

-98.44%

Current Drawdown

VIR:

-93.28%

VERU:

-97.60%

Fundamentals

Market Cap

VIR:

$765.26M

VERU:

$83.41M

EPS

VIR:

-$3.83

VERU:

-$0.21

Total Revenue (TTM)

VIR:

$16.73M

VERU:

$10.61M

Gross Profit (TTM)

VIR:

$11.69M

VERU:

$4.03M

EBITDA (TTM)

VIR:

-$462.00M

VERU:

-$29.34M

Returns By Period

In the year-to-date period, VIR achieves a -23.98% return, which is significantly lower than VERU's -12.41% return.


VIR

YTD

-23.98%

1M

-32.12%

6M

-27.91%

1Y

-41.08%

5Y*

-28.14%

10Y*

N/A

VERU

YTD

-12.41%

1M

8.55%

6M

-25.99%

1Y

-31.35%

5Y*

-28.35%

10Y*

-15.90%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

VIR vs. VERU — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

VIR
The Risk-Adjusted Performance Rank of VIR is 2626
Overall Rank
The Sharpe Ratio Rank of VIR is 2929
Sharpe Ratio Rank
The Sortino Ratio Rank of VIR is 2727
Sortino Ratio Rank
The Omega Ratio Rank of VIR is 3030
Omega Ratio Rank
The Calmar Ratio Rank of VIR is 2626
Calmar Ratio Rank
The Martin Ratio Rank of VIR is 1818
Martin Ratio Rank

VERU
The Risk-Adjusted Performance Rank of VERU is 4545
Overall Rank
The Sharpe Ratio Rank of VERU is 4040
Sharpe Ratio Rank
The Sortino Ratio Rank of VERU is 5252
Sortino Ratio Rank
The Omega Ratio Rank of VERU is 5252
Omega Ratio Rank
The Calmar Ratio Rank of VERU is 3535
Calmar Ratio Rank
The Martin Ratio Rank of VERU is 4343
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

VIR vs. VERU - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Vir Biotechnology, Inc. (VIR) and Veru Inc. (VERU). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for VIR, currently valued at -0.48, compared to the broader market-2.00-1.000.001.002.00
VIR: -0.48
VERU: -0.27
The chart of Sortino ratio for VIR, currently valued at -0.48, compared to the broader market-6.00-4.00-2.000.002.004.00
VIR: -0.48
VERU: 0.42
The chart of Omega ratio for VIR, currently valued at 0.95, compared to the broader market0.501.001.502.00
VIR: 0.95
VERU: 1.06
The chart of Calmar ratio for VIR, currently valued at -0.45, compared to the broader market0.001.002.003.004.00
VIR: -0.45
VERU: -0.32
The chart of Martin ratio for VIR, currently valued at -1.36, compared to the broader market-10.000.0010.0020.00
VIR: -1.36
VERU: -0.57

The current VIR Sharpe Ratio is -0.48, which is lower than the VERU Sharpe Ratio of -0.27. The chart below compares the historical Sharpe Ratios of VIR and VERU, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-0.500.000.501.001.502.00NovemberDecember2025FebruaryMarchApril
-0.48
-0.27
VIR
VERU

Dividends

VIR vs. VERU - Dividend Comparison

Neither VIR nor VERU has paid dividends to shareholders.


TTM20242023202220212020201920182017201620152014
VIR
Vir Biotechnology, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
VERU
Veru Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%3.57%

Drawdowns

VIR vs. VERU - Drawdown Comparison

The maximum VIR drawdown since its inception was -93.28%, smaller than the maximum VERU drawdown of -98.44%. Use the drawdown chart below to compare losses from any high point for VIR and VERU. For additional features, visit the drawdowns tool.


-100.00%-95.00%-90.00%-85.00%NovemberDecember2025FebruaryMarchApril
-93.28%
-97.60%
VIR
VERU

Volatility

VIR vs. VERU - Volatility Comparison

The current volatility for Vir Biotechnology, Inc. (VIR) is 16.39%, while Veru Inc. (VERU) has a volatility of 34.49%. This indicates that VIR experiences smaller price fluctuations and is considered to be less risky than VERU based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%20.00%40.00%60.00%80.00%NovemberDecember2025FebruaryMarchApril
16.39%
34.49%
VIR
VERU

Financials

VIR vs. VERU - Financials Comparison

This section allows you to compare key financial metrics between Vir Biotechnology, Inc. and Veru Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab